Investors who own more than 5% of a class must file a Schedule 13D or 13G. Each filer's latest filing for 75340L104 since 12/18/2024, largest first.
| Filer | % of Class | Filed | |
|---|---|---|---|
|
Bain Capital Life Sciences Fund, L.P.
13G/A
|
16.8% |
8/14/2026
Event 6/30/2026
|
|
| Bain Capital Life Sciences Fund, L.P. | 16.8% | ||
| BCIP Life Sciences Associates, LP | 1.7% | ||
|
Longitude Capital Partners II, LLC
13G/A
|
8.6% |
5/15/2026
Event 3/31/2026
|
|
| Longitude Capital Partners II, LLC | 8.6% | ||
| Longitude Venture Partners II, L.P. | 8.6% | ||
| Longitude Prime Partners, LLC | 0% | ||
| Longitude Prime Fund, L.P. | 0% | ||
| Patrick G. Enright | 8.6% | ||
| Juliet Tammenoms Bakker | 8.6% | ||
|
Armistice Capital, LLC
13G
|
7.3% |
8/14/2026
Event 6/30/2026
|
|
| Armistice Capital, LLC | 7.3% | ||
| Steven Boyd | 7.3% | ||
| Spignesi Robert G. Jr. 13D | 6.3% |
8/19/2025
Event 3/28/2024
|
|
|
Endeavour Medtech Growth II LP
13G/A
|
5.7% |
2/13/2026
Event 12/31/2025
|
|
| Endeavour Medtech Growth II LP | 5.7% | ||
| Endeavour Medtech Growth II Parallel LP | 5.7% | ||
| Endeavour Medtech II GP Limited | 5.7% |
| Period | Filings | Shares, Excl. Options | Value, Excl. Options |
|---|---|---|---|
| 2026 Q3 | 7 | 132 k | $136 k |
| 2026 Q2 | 35 | 18.1 M | $31.3 M |
| 2026 Q1 | 47 | 16.4 M | $37.3 M |
| 2025 Q4 | 43 | 15.3 M | $44.4 M |
| 2025 Q3 | 31 | 15.5 M | $51.7 M |
| 2025 Q2 | 31 | 15.8 M | $54.5 M |
| 2025 Q1 | 30 | 16.0 M | $42.1 M |
| 2024 Q4 | 21 | 12.6 M | $11.3 M |
| 2024 Q3 | 22 | 18.5 M | $16.5 M |
| 2024 Q2 | 25 | 19.7 M | $13.0 M |
| 2024 Q1 | 28 | 20.3 M | $19.5 M |
| 2023 Q4 | 31 | 21.7 M | $16.1 M |
| 2023 Q3 | 25 | 22.1 M | $23.9 M |
| 2023 Q2 | 26 | 22.5 M | $22.5 M |
| 2023 Q1 | 33 | 23.5 M | $35.4 M |
| 2022 Q4 | 45 | 25.2 M | $28.5 M |
| 2022 Q3 | 55 | 26.3 M | $84.9 M |
| 2022 Q2 | 54 | 26.8 M | $115 M |
| 2022 Q1 | 62 | 27.4 M | $186 M |
| 2021 Q4 | 57 | 21.8 M | $232 M |
| 2021 Q3 | 50 | 21.8 M | $401 M |